Biodesix Reports 34% Revenue Growth to $26.9 Million in Q2 2026

Biodesix, Inc. reported significant financial performance improvements in its quarterly filing for the period ending June 30, 2026. The company generated total revenues of $26.9 million, marking a 34% increase compared to $20.0 million in the same period last year. This growth was primarily driven by a 42% increase in Diagnostic Tests revenue, which reached $25.3 million, attributed to a 38% rise in test volumes to 20,900 and enhanced average revenue per test. In contrast, Development Services revenue decreased to $1.5 million from $2.1 million, reflecting timing issues in project completion.

The company's operating expenses for the second quarter were $32.2 million, an 8% increase from $29.7 million in the prior year. Notably, the net loss for the quarter was $7.3 million, a 37% improvement from the $11.5 million loss reported in the same quarter of 2025. This reduction in losses was attributed to higher revenues and improved operational efficiencies, leading to a gross margin of 82%, up 200 basis points year-over-year.

In terms of strategic developments, Biodesix has focused on expanding its sales and marketing efforts, which contributed to the increased test volumes. The company has also been actively involved in clinical studies to support the utility of its tests, including the ongoing INSIGHT and ALTITUDE studies. These initiatives are expected to enhance the clinical evidence supporting the company's diagnostic tests, potentially leading to broader payer coverage and increased adoption.

Operationally, Biodesix reported a cash and cash equivalents balance of $30.0 million as of June 30, 2026, a 17% increase from the previous quarter. This increase was bolstered by approximately $23.9 million in gross proceeds from the issuance of common stock under its at-the-market program. The company continues to maintain a strong liquidity position, which is crucial for funding ongoing research and development initiatives.

Looking ahead, Biodesix remains optimistic about its growth trajectory, driven by its expanding portfolio of diagnostic tests and services. The company anticipates continued revenue growth from its Diagnostic Tests segment, supported by improved payer coverage and operational efficiencies. However, it acknowledges the inherent risks associated with market conditions and reimbursement dynamics that could impact future performance.